Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

Abstract

The GEMOX regimen demonstrated a modest antitumor activity and is well tolerated in patients with advanced BTCs.

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

“…Although the combination of these drugs improves the progression-free and overall survival compared with gemcitabine alone, the median overall survival is still modestly approaching 1 year in metastatic CCA 244 . If cisplatin is contraindicated (for example, in renal insufficiency), safety and efficacy using gemcitabine in combination with oxaliplatin have been demonstrated in several phase II studies 248,249 . When gemcitabine and cisplatin fail, no established standard regimens in the second-line setting are available 250 .…”

Hepatobiliary Cancers, Version 2.2014

“…Based on these results, the combination of gemcitabine and cisplatin is considered to be the standard of care for first-line chemotherapy for patients with advanced or metastatic biliary tract cancers. Examples of other gemcitabine-based or fluoropyrimidine-based (fluorouracil or capecitabine) regimens with demonstrated activity in phase II trials include gemcitabine and cisplatin or oxaliplatin [165][166][167][168][169][170][171][172][173] ; gemcitabine and fluoropyrimidine [174][175][176][177][178][179] ; and fluoropyrimidine and oxaliplatin or cisplatin. [180][181][182][183] Triple-drug chemotherapy regimens also have been shown to be effective in patients with advanced biliary tract cancers, albeit in a very small number of patients.…”

Therapeutic options for intrahepatic cholangiocarcinoma

“…Further number of phase II studies suggested that oxaliplatin added to gemcitabine (GEMOX) may have comparable historical outcomes than cisplatin with a range of reported OS of 8.3 to 11 months (25)(26)(27)(28)(29). A recent randomized phase II trial suggested that GEMOX may be superior to 5-FU or best supportive care (BSC) alone (OS 9.5 vs. 4.5 vs. 4.6 months respectively, P=0.032) (30).…”